Recent Updates
Recently added Catalysts

White Blood Cells/Granulocytes

Phase 1

Solid Tumors | Monoclonal antibody | Oncology |Bone Biologics Corp|Last Updated: May 1, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment29

FDA Designations

No designations recorded

Clinical trial landscape

White Blood Cells/Granulocytes · 1 trial · 1 indication

Phase 1 1
NCT00900497A Study Using White Blood Cells From Healthy Donors To Treat Solid CancersSolid Tumors
ENROLLING BY_INVITATION29 Analytics
PHASE1ENROLLING BY_INVITATION
A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers
Solid Tumors
NCT0090049729
Unlock trial analytics

Study Endpoints

Primary Endpoints

The trial will observe the subject's cancer status for 3 months after the granulocyte infusions are completed. Response at 90 days will be based on comparison of tumor measurements at baseline.
90 to 100 days post treatment

Secondary Endpoints

The trial will evaluate the safety and dose tolerance of the transfusion of non-irradiated granulocytes (approximately 4 to 6 donors to reach a level of 2 x 10 to the 11th cells) from HLA-mismatched donors
1 to 2 weeks treatment and 30 days post treatment
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
White Blood Cells/GranulocytesEXPERIMENTALFresh, non-irradiated granulocytes from ABO-Rh compatible, HLA-mismatched donors

Interventions

NameTypeDescription
White Blood Cells/GranulocytesBIOLOGICALGranulocytes collected by apheresis, cross-matched for ABO-Rh and common antibodies, HLA-mismatched to avoid engraftment
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria for Subjects: * Must have signed Subject Informed Consent form * Documentation of Disease: All patients must have histologically or cytologically confirmed non-hematological malignancy that is metastatic or unresectable and for which standard curative or palliative measures do no...

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Other Solid Tumors 9 trials (matched to "Solid Tumors")

CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK2PHASE2pembrolizumab
Incyte CorporationINCY1PHASE2Chemotherapy, Retifanlimab
Iovance Biotherapeutics IncIOVA2PHASE2E7 TCR-T cells, Aldesleukin
Novartis AG Sponsored ADRNVS1PHASE1KFA115, pembrolizumab
AstraZeneca PLCAZN1 - Trastuzumab deruxtecan
Unlock Competitive Intelligence

Frequently asked questions about White Blood Cells/Granulocytes

What is White Blood Cells/Granulocytes used for in Solid Tumors?

White Blood Cells/Granulocytes is an investigational monoclonal antibody being developed for the treatment of solid tumors. It is currently in Phase 1 clinical development. The therapy involves using white blood cells from healthy donors to treat solid cancers, as part of an uncontrolled, biomarker-selected study.

What does White Blood Cells/Granulocytes target?

White Blood Cells/Granulocytes is a monoclonal antibody, but its specific molecular target has not been disclosed. The therapy is being studied for its potential to treat solid tumors by using white blood cells from healthy donors. The exact mechanism of action is not publicly detailed.

Who makes White Blood Cells/Granulocytes?

White Blood Cells/Granulocytes is being developed by Bone Biologics Corp (NASDAQ: BBLG). The company is conducting a Phase 1 clinical trial to evaluate the therapy in patients with solid tumors. The trial is enrolling by invitation in the United States.

What phase is White Blood Cells/Granulocytes in?

White Blood Cells/Granulocytes is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA. The ongoing Phase 1 trial is enrolling by invitation and is designed to assess the treatment in patients with solid tumors.

What clinical trials is White Blood Cells/Granulocytes in?

White Blood Cells/Granulocytes is being studied in one clinical trial, NCT00900497, titled 'A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers.' This Phase 1 trial is enrolling by invitation, with an estimated enrollment of 29 participants, and is being conducted in the United States.